Brazil starts production of AstraZeneca COVID-19 vaccine
Coronavirus Pandemic
BRAZIL started large-scale production of the AstraZeneca vaccine at the country’s key Fiocruz research facility in Rio de Janeiro, according to local media reports on Tuesday.
The vaccine produced with drugs imported from China has passed the necessary tests and 3.8 million doses can be expected to be handed over to the Health Ministry in Brasilia by the end of March.
The recent arrival of a shipment of raw materials to make 12.2 million doses of the AstraZeneca vaccine had raised new hopes for a vaccination breakthrough amid the rapid spread of the coronavirus in Brazil.
With Fiocruz, Brazil has a vaccine factory that is considered the largest in Latin America.
By the middle of the year, Fiocruz wants to produce a good 110 million doses of AstraZeneca’s coronavirus vaccine using imported pharmaceuticals.
In the second half of the year, thanks to technology transfers, it will be able to produce further 110 million doses completely independently.
The South American country started vaccinations in January.
So far, more than 11 million people have been proven to be infected with the coronavirus in Brazil.
More than 266,000 patients have died as a result of the virus. Higher numbers have only been recorded in the United States and India.
Most recently, Brazil experienced its worst week in the pandemic to date, with around 10,000 coronavirus deaths in seven days. (dpa/NAN)
– Mar. 9, 2021 @ 13:39 GMT
Related Posts
Nepal reaches out to other countries for jabs amid raging second wave
NEPAL is using all platforms available to reach out to the international community to procure vaccines amid the devastating…
Read MoreNigeria to reserve 50% of AstraZeneca supply due to anticipated delay
FAISAL Shuaib, executive director of the National Primary Health Care Development Agency, NPHCDA, has said that only...
Read MoreIndia records 352,000 new daily COVID-19 cases, 2,812 deaths
INDIA on Monday saw a new global record of 352,991 daily new COVID-19 infections as a second wave of the...
Read MoreMost Read
Subscribe to Our Newsletter
Keep abreast of news and other developments from our website.